Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)

v3.22.0.1
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)
6 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Stockholders Equity [Table Text Block]
   

Bio-Techne Shareholders

                 
                                   

Accumulated

                 
                   

Additional

           

Other

                 
   

Common Stock

   

Paid-in

   

Retained

   

Comprehensive

   

Noncontrolling

         
   

Shares

   

Amount

   

Capital

   

Earnings

   

Income(Loss)

   

Interest

   

Total

 

Balances at June 30, 2021

    38,955     $ 390     $ 534,411     $ 1,085,461     $ (57,291

)

  $ 8,263     $ 1,571,234  

Net earnings

                            69,615               (634

)

    68,981  

Other comprehensive income (loss)

                                    (6,925

)

    (39

)

    (6,964

)

Share repurchases                                                        

Common stock issued for exercise of options

    295       3       36,345       (13,481

)

                    22,867  

Common stock issued for restricted stock awards

    20       0       0       (9,765

)

                    (9,765 )

Cash dividends

                            (12,493

)

                    (12,493 )

Stock-based compensation expense

                    11,396                               11,396  

Common stock issued to employee stock purchase plan

    3       0       1,358                               1,358  

Employee stock purchase plan expense

                    341                               341  

Balances at September 30, 2021

    39,273     $ 393     $ 583,851     $ 1,119,337     $ (64,216

)

  $ 7,590     $ 1,646,955  

Net earnings

                            80,173             (8,114 )     72,059  

Other comprehensive income (loss)

                                    4,742       66       4,808  
Share repurchases     (89 )     (1 )             (41,293 )                     (41,294 )

Common stock issued for exercise of options

    134       1       18,604                               18,605  

Common stock issued for restricted stock awards

    1                                                  

Cash dividends

                            (12,576 )                     (12,576 )

Stock-based compensation expense

                    13,701                               13,701  
Common stock issued to employee stock purchase plan                     6                               6  

Employee stock purchase plan expense

                    267                               267  

Balances at December 31, 2021

    39,319       393       616,429       1,145,641       (59,474 )     (458 )     1,702,531  
   

Bio-Techne Shareholders

                 
                                   

Accumulated

                 
                   

Additional

           

Other

                 
   

Common Stock

   

Paid-in

   

Retained

   

Comprehensive

   

Noncontrolling

         
   

Shares

   

Amount

   

Capital

   

Earnings

   

Income(Loss)

   

Interest

   

Total

 

Balances at June 30, 2020

    38,453     $ 385     $ 420,536     $ 1,057,470     $ (97,199

)

  $ -     $ 1,381,192  

Cumulative effect adjustments due to adoption of new accounting standards

                            (276

)

                    (276

)

Net earnings

                            33,395                       33,395  

Other comprehensive income (loss)

                                    14,057               14,057  

Common stock issued for exercise of options

    117       1       13,727                               13,728  

Common stock issued for restricted stock awards

    25       0       (0

)

    (4,890

)

                    (4,890

)

Cash dividends

                            (12,336

)

                    (12,336

)

Stock-based compensation expense

                    12,667                               12,667  

Common stock issued to employee stock purchase plan

    6       0       1,463                               1,463  

Employee stock purchase plan expense

                    286                               286  

Balances at September 30, 2020

    38,601     $ 386     $ 448,679     $ 1,073,362     $ (83,142

)

  $ -     $ 1,439,285  

Non-controlling interest in Eminence

                                            8,985       8,985  

Net earnings

                            46,274             (130

)

    46,144  

Other comprehensive income (loss)

                                    18,904       83       18,987  

Common stock issued for exercise of options

    161       2       16,748       (2,482

)

                    14,268  

Common stock issued for restricted stock awards

    3       0       (0

)

    0                       0  

Cash dividends

                            (12,392

)

                    (12,392

)

Stock-based compensation expense

                    15,471                               15,471  

Employee stock purchase plan expense

                    106                               106  

Balances at December 31, 2020

    38,765     $ 388     $ 481,004     $ 1,104,762     $ (64,238

)

  $ 8,938     $ 1,530,854  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
   

Unrealized

Gains

(Losses) on

Derivative

Instruments

   

Foreign

Currency

Translation

Adjustments

   

Total

 

Balance as of June 30, 2021

  $ (6,193

)

  $ (51,098

)

  $ (57,291

)

Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne

    1,682       (6,750 )     (5,068 )

Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)

    2,884     $ -     $ 2,884  

Balance as of December 31, 2021(2)

  $ (1,626 )     (57,848 )     (59,474 )
   

Unrealized

Gains

(Losses) on

Derivative

Instruments

   

Foreign

Currency

Translation

Adjustments

   

Total

 

Balance as of June 30, 2020 attributable to Bio-Techne

  $ (13,253

)

  $ (83,946

)

  $ (97,199

)

Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne

    (47 )     28,759       28,712  

Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne (3)

    4,249       -       4,249  

Balance as of December 31, 2020(2)

  $ (9,051

)

  $ (55,187

)

  $ (64,238

)